Genetic Material Ingredients TRIZ Cases

Ambient or condenser air temperature triggers evaporator fan cycling to regulate suction pressure and prevent compressor overload.

Targeted AAV5 capsid mutations in the GH loop improve cardiac fibroblast transduction and tissue selectivity while preserving low immunogenicity.

Detargeting miRNA guide strands with tissue-specific binding sites suppresses liver and heart off-target expression in rAAV gene therapy.

A 10-amino-acid insertion at AAV-8 capsid positions 590-591 improves intravitreal retinal targeting and gene expression while reducing liver leakage.

Spacer sequences and inverted terminal repeats improve viral genome packaging while reducing contaminating nucleic acids in gene therapy vectors.

Adamantane-core ionizable lipidoids improve nucleic acid transfection while lowering cytotoxicity in mRNA, siRNA, and DNA delivery.

Non-viral transcription factor delivery reprograms diseased musculoskeletal cells to restore healthy phenotypes while avoiding viral integration risks.

Codon-optimized mRNA and a modified OTC protein improve mitochondrial delivery stability, sustain enzyme activity, and lower ammonia levels.

A rapid T cell engineering process uses pre-stimulation and timed viral transduction to preserve potency, persistence, and lower differentiation.

Computationally selected regulatory elements boost diaphragm-specific transgene expression while preserving tissue specificity and enabling lower vector doses.

Adamantane-core ionizable lipidoids improve nucleic acid transfection while lowering cytotoxicity for mRNA, siRNA, and DNA delivery.

A sub-2600 bp DNA vector removes antibiotic resistance and viral sequences to improve safe cellular delivery and therapeutic gene expression.

Reporter AAV assays measure neutralizing antibodies in serum and synovial fluid to guide vector choice and dosing before gene transfer.

A water-immiscible fluid displaces blood at a vessel target site, trapping the active agent locally to limit systemic spread and healthy-cell damage.

Specific VP1 capsid mutations improve biodistribution and transduction in CNS, muscle, and cardiac muscle for gene delivery.

AIL-region mutations in pri-miRNA shift single- and double-cut pre-miRNA production to tune expression without off-target effects.

Engineered AAV capsids use targeted amino acid changes to improve liver cell delivery across species while maintaining production yield.

Deamidated recombinant AAV capsids and AAV-SGA improve genome isolation accuracy while expanding tissue tropism and reducing immunity limits.

An intron-gated suicide gene exploits mutant spliceosomes to kill tumor cells while avoiding expression in normal cells.

Surface cysteine mutations let AAV capsids covalently bind ligands, nanoparticles, or drugs to improve cell targeting and reduce broad tropism.

Stimulated primary T cells are virally transduced and harvested within days, avoiding expansion while preserving potency and memory-like cell states.

Biodegradable disulfide ionizable lipids improve nucleic acid encapsulation and uptake while reducing inflammation, tissue accumulation, and cytotoxicity.

Non-viral transcription factor delivery reprograms diseased musculoskeletal cells to restore healthy tissue while avoiding viral immunogenic and mutagenic risks.

Engineered AAV9 capsids use a 7-amino acid insertion to improve CNS tropism and transgene expression for neurological gene delivery.

Modified ITRs block plasmid backbone DNA packaging in AAV vectors, improving gene expression while reducing random integration risk.

A synthetic enhancer-promoter boosts rAAV expression of large CFTR genes in airway epithelium despite tight packaging limits.

A dgRNA activation library enables gain-of-function screening in primary CD8+ T cells to find genes that enhance degranulation and anti-tumor activity.

Immunomodulators added to nucleic acid particles reduce inflammatory response, improve stability, and support higher protein expression.

LNP-delivered repressors target MYC promoters or super-enhancers to silence an undruggable cancer gene without binding the MYC protein.

X-ray radiolysis generates H2O2 to activate dTRPA1 neurons, enabling non-invasive neuromodulation with precise regional control.

Targeted capsid sequence changes improve AAV payload delivery to retinal and choroid/RPE tissues while preserving capsid integrity.

Coupling a peptide to siRNA suppresses TLR-linked immune gene activation, reducing inflammation and flu-like side effects in gene therapy.

Encoded PD-1 antibodies are produced in vivo from recombinant DNA, reducing protein manufacturing cost while sustaining antitumor immune response.

Limited proliferation and uneven cell quality are addressed by forcing MYC-family and BMI1 expression to produce cells with controlled differentiation states.